Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.
J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.
Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.
President Trump is hitting imports with massive new tariffs starting October 1st, targeting branded drugs (100%), heavy trucks (25%), and furniture.
JNJ-1900 offers new hope for advanced melanoma patients whose cancer progressed after many treatments, including anti-PD-1. Injected into tumors, activated by radiation, then combined with anti-PD-1, it shows promising early safety and efficacy signals, potentially boosting the immune system.
